PepLabo Download

Saxenda® (liraglutide) and hair loss

Hair loss on Saxenda®: alopecia is only in the US post-approval list, not the trial tables. What reports and reviews add, timing and when to seek help.

Published · Updated · Saxenda®: side effects by symptom · Written by the PepLabo editorial team

When to get help
Context and scope

Noticing more hair in the shower drain a few months into a daily Saxenda® injection is unsettling, and it is natural to ask whether the medicine is responsible. The official documents give a partial answer: hair loss is named in one place in the US label, but none of the placebo-controlled trial tables count it. This page sets out exactly where it appears, what pharmacovigilance research and a recent review say about liraglutide, why shedding often follows weight loss, and which patterns deserve a doctor’s look.

Key takeaways 5
  • The US label lists alopecia among post-approval reports for liraglutide, next to cutaneous amyloidosis, with no frequency given. [1]
  • Neither the US adult table (≥2% and above placebo) nor the adolescent table (≥3%) includes hair loss, and the EU and Canadian documents do not list it at all. [1][2][3]
  • In a European database of suspected reactions, alopecia made up 0.81% of reports for liraglutide, a medicine whose EU summary does not mention it. [4]
  • A 2026 systematic review found fewer studies on liraglutide and lower reported hair-loss risk than with semaglutide or tirzepatide. [5]
  • Shedding triggered by physical stress such as fast weight loss usually starts months later and is usually temporary. [6][7]

One line in the label, none in the trial tables

Saxenda® is liraglutide 3 mg, injected once a day for weight management in adults and in adolescents aged 12 to 17 who weigh more than 60 kg. [1] Its side effects are documented in three official places, and each counts them differently. The US tables include reactions seen in at least 2% of adults (3% of adolescents) and more often than on placebo; the EU table sorts reactions into frequency bands; the Canadian table goes down to 1%. [1][2][3]

Hair loss clears none of these thresholds. It turns up only in section 6.2 of the US label, a list of reactions reported after approval from a population of unknown size, where the label itself says frequency and causation cannot be reliably established. [1]

Hair loss in Saxenda® product information (checked 20-10-2026)
DocumentWhat it coversHair loss
US label, Table 2 [1]Adults, 5 placebo-controlled trials, up to 56 weeksNot listed
US label, Table 3 [1]Adolescents 12–17, one 56-week trialNot listed
US label, section 6.2 [1]Voluntary post-approval reports for liraglutideAlopecia listed, no rate
EU SmPC, section 4.8 [2]Adults, 5 trials, plus post-marketing reportsNot listed
Canadian monograph, sections 8.2–8.5 [3]Adults (≥1%), adolescents, less common and post-market reactionsNot listed

What reporting databases and reviews add

A 2026 analysis of EudraVigilance, the European database of suspected side effects, looked for reactions reported with semaglutide, liraglutide and tirzepatide that the respective EU summaries do not list. Alopecia accounted for 0.81% of the liraglutide reports. [4] Reports like these come from patients and professionals who suspected a link; they cannot show that the medicine caused the hair loss, and they cannot tell you how often it happens.

A 2026 systematic review pooled 24 studies on GLP-1 medicines and hair loss. Semaglutide and tirzepatide had the highest reported rates and the most frequent safety signals, while liraglutide was studied less and generally showed lower reported risk. Telogen effluvium and pattern hair loss were the main types described, women appeared to be affected more often, and rapid weight loss stood out as a likely contributor. [5] The authors note that causation and timing still need prospective trials.

Why shedding can follow a weight-loss medicine

  • Supported by the label: nothing beyond the listing itself. The Saxenda® label does not describe a mechanism for alopecia or tie it to a dose. [1]
  • Proposed in research: the 2026 review points to fast weight loss as a trigger for telogen effluvium, a shift of many growing hairs into the resting phase at once. [5] Cleveland Clinic lists rapid weight loss and restrictive diets among the triggers. [7]
  • General medical knowledge: MedlinePlus explains that physical or emotional stress can make a large share of scalp hair shed, and that crash diets low in protein are one recognised cause. [6] Eating much less, which is how liraglutide lowers weight according to the label, is a change the body notices. [1]

Timing on a daily injection

Telogen effluvium is delayed. Cleveland Clinic describes shedding that typically appears two to three months after the trigger, and MedlinePlus notes it may not be noticed for weeks to months, then eases over six to eight months. [6][7] Hair often comes out in handfuls while washing or brushing, as general thinning rather than bald patches. [6][7]

Set that against the Saxenda® schedule. The dose rises every week from 0.6 mg to 3 mg by week five, and the label asks prescribers to check weight at week 16 and stop treatment in adults who have not lost at least 4% of their starting weight. For adolescents, the check is a 1% fall in BMI after 12 weeks on the maintenance dose. [1] Shedding that began after the early weight change may therefore show up close to that review, which is a natural moment to mention it.

Other reasons hair thins

MedlinePlus lists many causes unrelated to any weight-loss medicine: inherited pattern hair loss, thyroid disease, anaemia, hormone changes, childbirth, high fever or major illness, surgery, alopecia areata (round bald patches), scalp infections, tight hairstyles and some medicines, including certain antidepressants, beta-blockers and birth control pills. [6] Several of these, such as thyroid problems and low iron, can be checked with blood tests when a clinician thinks they are likely. [6][7]

The pattern matters. Diffuse thinning a few months after a big change fits telogen effluvium; patches, scarring, scalp pain or redness point elsewhere. [6]

What official and clinical sources describe

For shedding linked to illness or medicine use, MedlinePlus says hair usually regrows without treatment, and Cleveland Clinic reports that most acute telogen effluvium resolves, with regrowth visible after the shedding period. [6][7] Cleveland Clinic advises against extreme or restrictive diets and suggests asking a healthcare provider before starting any supplement. [7]

The Saxenda® Medication Guide asks you to tell your provider about all medicines, vitamins and herbal supplements you take, and to talk to them about any side effect that bothers you or does not go away. [1] It does not suggest stopping the medicine because of hair changes; that is a decision for your prescriber.

Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help

The signs and contact information below come from this article’s sourced guidance.

Emergency

  • Trouble breathing, a swollen face or throat, or a widespread itchy rash

    Contact: Emergency services (911 / 112)

    Medication Guide [1]

At your next appointment

  • Hair loss in patches, or with scalp pain, itching, redness or scaling

    Contact: Your doctor or a dermatologist

    MedlinePlus [6]

  • Thinning together with tiredness, feeling cold, muscle weakness or weight gain

    Contact: Your doctor, to look for thyroid or other causes

    MedlinePlus [6]

  • A teenager on Saxenda® losing hair quickly

    Contact: The teen’s prescriber

    MedlinePlus [6]; label [1]

  • Shedding that continues beyond six months

    Contact: Your prescriber or a dermatologist

    Cleveland Clinic [7]

Questions

Is hair loss a known side effect of Saxenda®?

Only as a post-approval report. The US label lists alopecia among reactions reported after approval, without a rate; it is not in the trial tables, the EU product information or the Canadian monograph. [1][2][3]

Will my hair grow back?

If the cause is telogen effluvium, the usual outlook is good: MedlinePlus describes it as usually temporary, and Cleveland Clinic reports that most acute cases resolve. [6][7] Patchy or scarring hair loss is different and needs an examination.

Is liraglutide less likely than semaglutide to cause hair loss?

A 2026 review found lower reported risk for liraglutide than for semaglutide or tirzepatide, but also far fewer studies, so the comparison is uncertain. [5]

My teenager is on Saxenda® and losing hair. What should we do?

The adolescent trial table does not list hair loss. [1] MedlinePlus advises contacting a provider when hair is lost rapidly at a young age, so raise it with the prescriber rather than waiting for the 12-week review. [6]

Should I stop Saxenda® if my hair is thinning?

The label does not tell you to stop for hair changes. [1] Talk to your prescriber first; they can look at the pace of weight loss and other causes before deciding anything.

Can supplements help?

Cleveland Clinic suggests asking a provider before adding supplements, and the Medication Guide asks you to report vitamins and herbal products you take. [1][7] A deficiency, if found, is treated by your doctor.

Sources

Sources checked on

  1. SAXENDA® (liraglutide) injection Prescribing Information and Medication Guide, Novo Nordisk Revised 02/2026. Sections 2.2, 6.1 (Tables 2–3), 6.2, 12.2, 17 and Medication Guide.
  2. Saxenda: EPAR – Product Information (SmPC and package leaflet), European Medicines Agency Section 4.8, Table 4.
  3. SAXENDA® (liraglutide injection) Product Monograph, Novo Nordisk Canada Inc. (Health Canada Drug Product Database) Date of authorization 10 September 2025. Sections 8.2 (Tables 3–4), 8.3 and 8.5.
  4. Popa Ilie IR et al. Incretin-based drugs for obesity: common and drug-specific reporting patterns of adverse drug reactions — a comparative disproportionality analysis using EudraVigilance reports integrating SmPC data. Pharmaceuticals 2026 Pharmacovigilance study; PubMed abstract.
  5. Gupta AK et al. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Sci Prog 2026 Systematic review of 24 studies; PubMed abstract.
  6. Hair loss, MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine)
  7. Telogen Effluvium, Cleveland Clinic

Keep exploring